Status:
RECRUITING
Bumetanide in Patients With Alzheimer's Disease
Lead Sponsor:
Stanford University
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of...
Eligibility Criteria
Inclusion
- Mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Alzheimer's disease medications are planned to remain stable throughout.
- Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI.
Exclusion
- Clinically significant abnormalities in screening laboratory tests
- Chronic liver disease
- Renal insufficiency
- Poorly managed hypertension
- Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.
Key Trial Info
Start Date :
April 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 15 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06052163
Start Date
April 10 2023
End Date
April 15 2025
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305